4.7 Article

Comparative analysis of molecular fingerprints in prediction of drug combination effects

Journal

BRIEFINGS IN BIOINFORMATICS
Volume 22, Issue 6, Pages -

Publisher

OXFORD UNIV PRESS
DOI: 10.1093/bib/bbab291

Keywords

drug combinations; drug synergy; molecular fingerprints; machine learning; precision medicine

Funding

  1. European Research Council (ERC) starting grant DrugComb (Informatics approaches for the rational selection of personalized cancer drug combinations) [716063]
  2. Integrative Life Science Doctoral Programme, University of Helsinki
  3. Academy of Finland [322675]
  4. Academy of Finland (AKA) [322675, 322675] Funding Source: Academy of Finland (AKA)

Ask authors/readers for more resources

This study compares rule-based and data-driven molecular representations in predicting drug combination sensitivity and synergy scores, using standardized results from high-throughput screening studies. The research highlights the importance of supplementing quantitative benchmark results with qualitative considerations for identifying the optimal molecular representation type.
Application of machine and deep learning methods in drug discovery and cancer research has gained a considerable amount of attention in the past years. As the field grows, it becomes crucial to systematically evaluate the performance of novel computational solutions in relation to established techniques. To this end, we compare rule-based and data-driven molecular representations in prediction of drug combination sensitivity and drug synergy scores using standardized results of 14 high-throughput screening studies, comprising 64 200 unique combinations of 4153 molecules tested in 112 cancer cell lines. We evaluate the clustering performance of molecular representations and quantify their similarity by adapting the Centered Kernel Alignment metric. Our work demonstrates that to identify an optimal molecular representation type, it is necessary to supplement quantitative benchmark results with qualitative considerations, such as model interpretability and robustness, which may vary between and throughout preclinical drug development projects.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available